Trouillas P, Serratrice G, Laplane D, Rascol A, Augustin P, Barroche G, Clanet M, Degos C F, Desnuelle C, Dumas R
Ataxia Research Center, Hôpital Neurologique, Lyons, France.
Arch Neurol. 1995 May;52(5):456-60. doi: 10.1001/archneur.1995.00540290042016.
To study the effect of the levorotatory form of 5-hydroxytryptophan on the cerebellar symptoms of Friedreich's ataxia.
Cooperative double-blind study of the levorotatory form of 5-hydroxytryptophan vs placebo.
Twelve centers in research hospitals.
Twenty-six patients were included; 19 completed the study (mean +/- SD age of patients, 25.9 +/- 8.1 years). Of these 19 patients, eight were treated with placebo and 11 were treated with the drug.
A semiquantitative scale for kinetic and static ("postural") cerebellar functions and quantitative measurements of time in standard tests that evaluated stance, speech, writing, and drawing.
In the active treatment group, a significant decrease of the kinetic score was observed (P = .03), indicating an improvement in coordination.
These results demonstrated that the levorotatory form of 5-hydroxytryptophan is able to modify significantly the cerebellar symptoms in patients with Friedreich's ataxia. However, the effect is only partial and not clinically major.